Zacks Research Has Negative Outlook for CORT FY2025 Earnings

Corcept Therapeutics Incorporated (NASDAQ:CORT) – Investment analysts at Zacks Research dropped their FY2025 EPS estimates for Corcept Therapeutics in a report released on Wednesday, December 18th. Zacks Research analyst K. Das now expects that the biotechnology company will earn $1.55 per share for the year, down from their prior estimate of $1.56. The consensus estimate for Corcept Therapeutics’ current full-year earnings is $1.35 per share.

A number of other research firms also recently issued reports on CORT. HC Wainwright reaffirmed a “buy” rating and issued a $80.00 price objective on shares of Corcept Therapeutics in a research note on Thursday, October 31st. StockNews.com cut shares of Corcept Therapeutics from a “strong-buy” rating to a “buy” rating in a research report on Monday, November 25th. Truist Financial increased their price objective on shares of Corcept Therapeutics from $65.00 to $76.00 and gave the company a “buy” rating in a research report on Monday, September 30th. Sandler O’Neill restated a “buy” rating on shares of Corcept Therapeutics in a report on Friday, October 18th. Finally, Piper Sandler increased their price target on shares of Corcept Therapeutics from $38.00 to $67.00 and gave the company an “overweight” rating in a report on Wednesday, September 18th. Six analysts have rated the stock with a buy rating, According to MarketBeat.com, Corcept Therapeutics has an average rating of “Buy” and an average target price of $65.25.

Corcept Therapeutics Price Performance

NASDAQ:CORT opened at $52.17 on Monday. The business’s 50-day moving average is $54.05 and its 200 day moving average is $42.28. Corcept Therapeutics has a 12 month low of $20.84 and a 12 month high of $62.22. The company has a market capitalization of $5.47 billion, a P/E ratio of 41.41 and a beta of 0.51. The company has a current ratio of 3.70, a quick ratio of 3.64 and a debt-to-equity ratio of 0.01.

Corcept Therapeutics (NASDAQ:CORT) last announced its quarterly earnings results on Wednesday, October 30th. The biotechnology company reported $0.41 EPS for the quarter, topping the consensus estimate of $0.27 by $0.14. The business had revenue of $182.55 million for the quarter, compared to analysts’ expectations of $171.97 million. Corcept Therapeutics had a net margin of 22.35% and a return on equity of 24.54%. The business’s quarterly revenue was up 47.7% compared to the same quarter last year. During the same quarter in the previous year, the company earned $0.28 EPS.

Institutional Trading of Corcept Therapeutics

Hedge funds and other institutional investors have recently bought and sold shares of the business. Hancock Whitney Corp boosted its stake in shares of Corcept Therapeutics by 1.2% during the third quarter. Hancock Whitney Corp now owns 22,954 shares of the biotechnology company’s stock valued at $1,062,000 after purchasing an additional 270 shares during the period. KBC Group NV boosted its position in Corcept Therapeutics by 21.3% in the 3rd quarter. KBC Group NV now owns 2,822 shares of the biotechnology company’s stock valued at $131,000 after buying an additional 496 shares during the period. Nisa Investment Advisors LLC grew its stake in Corcept Therapeutics by 10.5% in the 2nd quarter. Nisa Investment Advisors LLC now owns 5,368 shares of the biotechnology company’s stock worth $174,000 after acquiring an additional 510 shares in the last quarter. Capital Performance Advisors LLP purchased a new position in shares of Corcept Therapeutics during the third quarter worth approximately $25,000. Finally, Allspring Global Investments Holdings LLC raised its stake in shares of Corcept Therapeutics by 0.4% during the second quarter. Allspring Global Investments Holdings LLC now owns 127,348 shares of the biotechnology company’s stock valued at $4,138,000 after acquiring an additional 541 shares in the last quarter. Hedge funds and other institutional investors own 93.61% of the company’s stock.

Insiders Place Their Bets

In other Corcept Therapeutics news, insider William Guyer sold 3,394 shares of the firm’s stock in a transaction dated Monday, November 4th. The shares were sold at an average price of $48.97, for a total value of $166,204.18. Following the completion of the sale, the insider now owns 5,796 shares of the company’s stock, valued at $283,830.12. This trade represents a 36.93 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this hyperlink. Also, insider Gary Charles Robb sold 11,000 shares of the company’s stock in a transaction that occurred on Tuesday, October 1st. The shares were sold at an average price of $46.28, for a total value of $509,080.00. Following the transaction, the insider now directly owns 22,772 shares in the company, valued at approximately $1,053,888.16. This represents a 32.57 % decrease in their position. The disclosure for this sale can be found here. Insiders sold 26,811 shares of company stock valued at $1,341,360 over the last three months. 20.50% of the stock is owned by company insiders.

About Corcept Therapeutics

Corcept Therapeutics Incorporated engages in discovery and development of drugs for the treatment of severe endocrinologic, oncologic, metabolic, and neurologic disorders in the United States. It offers Korlym tablets medication for the treatment of hyperglycemia secondary to hypercortisolism in adult patients with endogenous cushing's syndrome; and who have type 2 diabetes mellitus or glucose intolerance and have failed surgery or are not candidates for surgery.